A LEGACY OF ACHIEVEMENT,
TOWARDS A FUTURE OF ACCOMPLISHMENT

OUR MISSION

At Omega Therapeutics, we are pioneering the discovery of epigenomic targets to develop a new class of therapeutics to fundamentally transform human medicine in the service of patients. Our objective is to become the leading digital and data-driven epigenetic medicines company by discovering and developing Omega Epigenomic Controllers (OECs), utilizing the OMEGA Epigenomic Programming™ platform, with the vision of selectively directing the human genome to treat and cure serious diseases.

OUR ETHOS

Our culture is inspired by our values and behaviors and is guided by our overarching ethos: Ambitious, yet humble.

Our team has the burning ambition to succeed in our pioneering journey, however, we are grounded in humility given the enormous responsibility of eventually treating patients with our transformative medicines.

Our Omega values reflect this ethos and are hallmarks of our high-performance culture.

VALUES

Trust

Resilience

Authenticity

Innovation

Leadership

WE ARE ON A MISSION
TO TREAT PATIENTS AND
CURE SERIOUS DISEASE WITH OUR
NEW CLASS OF EPIGENETIC MEDICINES.

ABOUT OMEGA

OUR COMPANY

Omega Therapeutics is a clinical-stage biotechnology company pioneering a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to transform human medicine. The OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics to rationally design biologically engineered, modular and programmable mRNA-encoded epigenetic medicines that target the fundamental structural and functional units of gene control. 

Omega Therapeutics was founded by Flagship Pioneering in 2017 and is currently advancing a broad pipeline of programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases. The Company intends to focus internal development and commercialization efforts in areas of high unmet need with well-defined and circumscribed patient populations. Omega’s mission is to transform medicine in the service of patients.

FOUNDED BY FLAGSHIP LABS IN 2017 Noubar Afeyan, Founder & Chairman
David Berry, Founder
CHIEF EXECUTIVE OFFICER Mahesh Karande
FOUNDING SCIENTIFIC ADVISORS Dr. Rudolf Jaenisch & Dr. Richard Young
MIT and Whitehead Institute
HEADQUARTERS Cambridge, MA

OUR MANAGEMENT TEAM

Mahesh Karande

President & CEO, Board Director

X

Mahesh Karande | President & CEO, Board Director

Mahesh Karande is deeply experienced in running biopharma businesses across discovery, preclinical development, clinical development, commercialization and product life cycle management stages. His breadth of therapeutic experience spans cardiovascular and metabolic, oncology, neurosciences, ophthalmology, antibiotics, pain, respiratory and rare and genetic diseases as well as drug and device combinations. He has been involved with more than 10 product launches in the U.S. and across global markets.

He has strong leadership, operational and business-building experiences combined with a global work history spanning the U.S., Europe, Asia and Africa.

Prior to taking the helm at Omega, Mr. Karande was President and CEO of Macrolide Pharmaceuticals, a company he took from discovery into early development. Earlier, Mr. Karande spent several years at Novartis in senior leadership roles: VP and Head of US Oncology for solid tumors, President of Novartis Africa and President of Novartis Egypt. He worked for McKinsey & Company prior to joining the bio-pharmaceutical industry.

Mr. Karande has an M.B.A. from the Wharton School, University of Pennsylvania. He is also a graduate of the Georgia Institute of Technology where he completed his M.S. in engineering and the University of Bombay where he completed undergraduate studies in engineering.

Thomas McCauley, Ph.D.

Chief Scientific Officer

X

Thomas McCauley | Chief Scientific Officer

Dr. Thomas McCauley joined Omega as chief scientific officer in August 2019. Prior to Omega, he served as CSO at Zikani Therapeutics (formerly Macrolide Pharmaceuticals) and before that at Translate Bio (formerly RaNA Therapeutics).

In these roles, Dr. McCauley was responsible for overall scientific vision, strategic direction and leadership of research and development. He provided scientific, technical and operational oversight for advancement of the company’s oligo, mRNA and novel macrocyclic technology platforms and management of portfolio therapeutic programs in pulmonary, metabolic, genetic and infectious disease.

Previously, Dr. McCauley served as vice president and head of Global Nonclinical Development at Shire Pharmaceuticals, where he made significant contributions to the development and global approvals of many of Shire's products, including Replagal® for Fabry disease, Vpriv® for Gaucher disease, Elaprase® for Hunter syndrome, Firazyr® for hereditary angioedema and Xiidra® for dry eye disease.

Dr. McCauley has more than 19 years of experience in the biotechnology and pharmaceutical industries and has authored more than 40 scientific publications, book chapters and patents. He holds undergraduate and graduate degrees from Cornell University and received his Ph.D. from the University of Alabama at Birmingham.

Kevin McManus
Kevin McManus

Chief Human Resources Officer

X

Kevin McManus | Chief Human Resources Officer

Kevin McManus joined Omega as Chief Human Resources Officer in March 2022. Prior to joining Omega, Kevin was most recently Senior Vice President and Chief Human Resources Officer at Acceleron Pharma, where he grew the organization to over 400 employees. Prior to this experience, he held various senior human resources roles of increasing responsibility at Bayer, most recently serving as Vice President and Human Resources Business Partner, Bayer Pharmaceuticals (Americas).

Previously, Kevin held senior human resources roles at Mylan Inc., The Ladders.com, ConvaTec, Inc., Bristol-Myers Squibb Company and GTE Corporation. In these roles, Kevin was responsible for leading internal human resources teams as well as expanding life science and biotechnology teams and attracting top talent by creating competitive programs and benefit policies.

Mr. McManus brings over 30 years of experience in many human resources roles supporting biotechnology, medical device and technology organizations, including over 15 years of experience leading global teams. His expertise lies in HR strategic planning, talent management, employee relations, M&A, and employee engagement retention. Kevin received his Bachelor of Science in Industrial and Labor Relations from Cornell University and certification as a Master Practitioner Organization Development from Ashridge University.

Yan Moore, M.D.

Chief Medical Officer

X

Yan Moore, M.D. | Chief Medical Officer

Dr. Yan Moore joined Omega as Chief Medical Officer in January 2022. Prior to Omega, he served as Senior Vice President, Head of Oncology Therapeutic Area at Ipsen Pharmaceuticals, and before that as Chief Medical Officer and Senior Vice President of Clinical Development and Research and Development at Anchiano Therapeutics (previously BioCanCell Therapeutics).

In these roles, Dr. Moore was responsible for identifying and executing research and development objectives in areas of oncology and immune-modulatory therapies, managing clinical and preclinical drug development (pre-IND to phase 1), scientific and development strategy, creation of internal drug development engines to support the overall portfolio strategies, and managing global medical affairs strategy.   

Previously, Yan held several senior roles of increasing responsibility at Ariad Pharmaceuticals, Sanofi Oncology, GlaxoSmithKline, BMS amongst others. As a clinician, Dr. Moore spent time at Sapir Medical Center, Meir Hospital and Edith Wolfson Medical Center.

Dr. Moore has over 20 years of experience in the biotechnology and pharmaceutical industries. Dr. Moore received his medical degree and Bachelor of Medical Sciences from the Sackler School of Medicine at Tel Aviv University, Master of Business Administration from the LeBow College of Business at Drexel University and completed the Advanced Management Program at Harvard Business School.

 

Joshua Reed

Chief Financial Officer

X

Joshua Reed | Chief Financial Officer

Joshua Reed joined Omega as Chief Financial Officer in May 2022 with over 25 years of successful and diverse corporate and financial operations experience. Prior to Omega, Mr. Reed most recently served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. During his time at Aldeyra, Mr. Reed led multiple capital raises, oversaw the company's interactions with current and prospective investors and managed all aspects of the company's financial processes, including quarterly and annual SEC filings..

Previously, Mr. Reed held a variety of finance roles of increasing responsibility at Bristol-Myers Squibb, most recently serving as Vice President and Head of Finance Operations for the United States and Puerto Rico. While at Bristol-Myers Squibb, Mr. Reed also led financial planning and analysis, supply chain and manufacturing finance, and worked on various acquisitions, divestitures, alliances, and collaboration agreements. Prior to joining the bio-pharmaceutical industry, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed began his career at JP Morgan Chase, Credit Suisse First Boston, and Chase Manhattan Bank. Mr. Reed currently serves on the Board of Directors and as Chairman of the Audit Committee of Scholar Rock, a publicly traded biotechnology company.

Mr. Reed received his Bachelor of Science in Finance from Rutgers University and his Master of Business Administration from the University of Michigan’s Ross School of Business.

Ling Zeng, Esq.

Chief Legal and Administrative Officer

X

Ling Zeng, Esq. | Chief Legal and Administrative Officer

Ling Zeng joined Omega as Chief Legal and Administrative Officer in March 2022. Prior to joining Omega, Ling was most recently Chief Legal Officer and Secretary of Dicerna Pharmaceuticals, where she worked alongside other executives, the board of directors and their committees to develop and implement company strategy, policy, governance and compliance. Earlier, Ms. Zeng served as Deputy Head Legal, Group Mergers and Acquisitions, at Novartis AG, where she was responsible for global transactions across the Novartis Group.

Ms. Zeng brings over 20 plus years of experience in the healthcare industry. Previously, she held various legal executive roles of increasing responsibility at Bausch Health Companies, Inc., Penwest Pharmaceuticals Co. and Barr Laboratories, Inc. In these roles, Ms. Zeng was responsible for providing sound counsel on public company governance, compliance, enterprise risk management, development and commercial operations, strategic transactions, healthcare industry regulations, and IP portfolio management and strategy. Ms. Zeng began her legal career at Cleary, Gottlieb, Steen and Hamilton and, prior to that, also spent time as a researcher at Alkermes Inc. and LeukoSite Inc.

Ms. Zeng received her Bachelor of Science in Physics from Peking University, Master of Science in Biophysics from Brandeis University, and Juris Doctor in Law from Georgetown University.

Barbara Chan

SVP, Finance

X

Barbara Chan | SVP, Finance

Barbara Chan brings over 20 years of experience as a senior finance leader in the biotechnology, pharmaceutical and life sciences industries to Omega. Prior to joining the Omega team, Barbara most recently served as Vice President of Finance and Chief Accounting Officer of Aegerion Pharmaceuticals.

Joining Aegerion at a particularly challenging time, Ms. Chan was able to completely transform and rebuild the finance organization, including significantly reducing the finance team turnover, establishing an appropriate control environment, improving internal processes, and enhancing both internal and external reporting. During her tenure at the company, Ms. Chan helped to support in the resolution of the significant legal and compliance issues facing the company, and led her team through a complex merger, two product launches outside of the U.S., and played a pivotal role in the ultimate sale of the company.

Prior to that, Ms. Chan spent 13 years with Parexel International, where she oversaw the company’s revenue growth from $320 million to over $2 billion. While at Parexel, she held roles of increasing responsibility, most recently as Global Head of Accounting Services.

Ms. Chan is a CPA with a B.S. in Accountancy and an M.S. in Taxation from Bentley University.

Sivakesava Sakhamuri, Ph.D.

SVP, Head of Technical Operations and Quality

X

Sivakesava Sakhamuri, Ph.D. | SVP, Head of Technical Operations and Quality

Siva Sakhamuri brings over 25 years of successful pharmaceutical manufacturing experience and leadership in bringing innovative medicines to patients. Mr. Sakhamuri has broad experience in clinical and commercial biologics, small molecule and vaccine manufacturing, CMC strategy, process development, external vendor/alliance and project management, regulatory support and life cycle product management. 

Prior to joining Omega, Siva was Head of Manufacturing for Alnylam’s internal and external manufacturing operations, including seminal contributions to the registration and launch of Onpattro®, Givlaari® and Oxlumo®. Before Alnylam, Siva was Executive Director, Global Tech Services, Process and Analytical Development at Alexion Pharmaceuticals, and earlier was Director, Manufacturing for Sanofi-Pasteur, where he was responsible for commercial vaccine product manufacturing and facility management. Siva began his industry career at Bristol-Myers Squibb Co. supporting global biologics manufacturing teams.

Siva received his Ph.D. degree in Biochemical Engineering from Indian Institute of Technology, completed a Postdoctoral Fellowship at the Korea Research Institute of Bioscience & Biotechnology, and additional Postdoctoral research at Hong Kong University of Science and Technology and Pennsylvania State University. 

Ramola
Ramola Bhandarkar

VP, Regulatory Affairs

X

Ramola Bhandarkar  | VP, Regulatory Affairs

Ramola Bhandarkar joined Omega as Vice President of Regulatory Affairs and brings over 20 years of experience in the biopharmaceutical industry working with a diverse range of therapeutics including cellular therapies, monoclonal antibodies, antibody drug conjugates, and small molecules.

Most recently, she was the Head of Regulatory Strategy for bluebird bio’s Oncology Business Unit and contributed toward building that team. She was responsible for providing strategic regulatory expertise for both early and late phase cellular therapy and gene-edited programs. During her time at bluebird bio, she was the bluebird bio global regulatory lead for ABECMA®, which recently earned the distinction of becoming the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. Prior to bluebird bio, Ramola held positions of increasing responsibility at ImmunoGen, Inc. where she led the clinical regulatory group which provided regulatory guidance for a number of early and late phase antibody drug conjugates to treat cancer. Earlier in her career, Ramola spent many years at Cephalon (now Teva Pharmaceuticals) and Organon, Inc. in pharmaceutical development.

Ramola received her M.S., Quality Assurance/Regulatory Affairs from Temple University, her M.S., Pharmaceutical Sciences from University of Missouri-Kansas City, and her Bachelor of Pharmacy from Pune University, India.

Lisamarie Fahy

VP, Clinical Development Operations

X

Lisamarie Fahy | VP, Clinical Development Operations

Lisamarie Fahy brings over 30 years of clinical experience, including expertise in clinical trial management and delivering high quality clinical development programs through global registration and approval, regulatory submissions with the FDA, EMEA and PMDA, marketing approvals and GCP compliance and inspections. Her experience spans both academic and industry settings with expertise in gene therapy, cardiovascular, oncology and rare disease programs.

Most recently, Ms. Fahy was Vice President, Head of Clinical Development Operations at AVROBIO.  Prior to AVROBIO, she served as Head of Global Clinical Development Operations at both H3 Biomedicine and Aegerion Pharmaceuticals. She also held various clinical development roles of increasing responsibility at Shire Pharmaceuticals and Wyeth Research. Ms. Fahy began her career as a clinical research and program coordinator at the Brigham and Women’s Hospital.

Ms. Fahy received an B.S. in Physiology from the University of Massachusetts.  

Qi-Ying
Qi-Ying Hu. Ph.D.

VP, Formulations

X

Dr. Qi-Ying Hu brings over 17 years of successful drug discovery experience in large pharma and biotech to Omega.  Most recently, he was Head of Chemistry and Delivery at Oncorus Therapeutics, where he was responsible for the development of the nonviral delivery platform for the delivery of oncolytic viral RNAs. He developed the in-house proprietary RNA delivery system and contributed significantly to the development of clinical candidates ONCO-021 and ONCO-788. 

Prior to Oncorus, he was Director of Drug Delivery at Decibel therapeutics, where he invented the inner ear targeting drug DB020 for the prevention of hearing loss, which is currently in phase 1 clinical trials. Before Decibel, Dr. Hu spent 12 years at Novartis Institutes for Biomedical Research (NIBR) in various roles leading discovery and platform development teams that advanced several candidates into clinical studies in cardiovascular and metabolism, oncology, and ophthalmology disease areas. He is a co-inventor of the FDA approved drug ISTURISA® (Osilodrostat) for Cushing's disease.

Dr. Hu is a thought leader in the drug discovery science. He has authored more than 60 scientific publications, book chapters and patents. He holds an undergraduate degree from Shanghai Medical College of Fudan University, received his PhD from the National University of Singapore, and completed a post-doctoral fellowship with Nobel Laureate Professor E. J. Corey at Harvard University.

Joe Newman, Ph.D.

VP, Biology

X

Joe Newman, Ph.D. | VP, Biology

Dr. Joe Newman has over 20 years of experience leading and supporting all stages of drug development, from lead optimization through to clinical development. Prior to joining Omega, Joe was Vice President of Early Development at Zikani Therapeutics, where he successfully transitioned the company’s focus from infectious diseases to oncology and rare diseases.

Prior to Zikani, he was the head of Biology at Tetraphase Therapeutics, leading the NDA and MAA submissions for Xerava®. Before that, Dr. Newman spent ten years at AstraZeneca in various roles supporting early development and IND submissions for a number of programs, including two products currently in Phase 3 clinical development.

Dr. Newman received his undergraduate degree in Biology from the University of Delaware, his Ph.D. in Molecular Microbiology from the University of Rhode Island and completed fellowships at Tufts Medical School and MIT.

charles o'donnell
Charles O’Donnell, Ph.D.

VP, Head of Computational Genomics and Data Sciences

X

Charles O’Donnell, Ph.D. | VP, Head of Computational Genomics and Data Sciences

Dr. Charles O’Donnell brings over 15 years of data science and genomics experience to Omega, with an extensive background using data to solve scientific problems, specifically in genetic medicines. He has successfully led multi-disciplinary teams and has proven a broad range of technical and strategic expertise across data science, computational biology, machine learning, genomics and epigenomics, NGS, editing, gene therapy, proteomics, systems and network analysis, high performance computing, and data integration.

Prior to joining Omega, Charles was Head of the Computational Biology and Data Sciences function at Evelo Biosciences, and the first Head of Computational Biology and Data Sciences at Camp4 Therapeutics. Earlier in his career, he was the computational subject-matter expert in Biogen’s Epigenetics and Cell and Gene Therapy team and worked as a joint NRSA Postdoctoral Fellow in the Melton Lab of Harvard’s Stem Cell Institute and the Gifford Lab of MIT’s Computer Science and AI Laboratory.

Dr. O’Donnell received his Ph.D. in Electrical Engineering and Computer Science from MIT, working in the Berger and Devadas Labs at MIT’s Computer Science and AI Laboratory and the Lindquist Lab of the Whitehead Institute. He received his M.S. in Electrical Engineering and Computer Science from MIT and his B.S. in Computer Engineering from Columbia University.

Samir
Samir Padalkar, Ph.D. 

VP, Data and IT

X

Samir Padalkar, Ph.D  | VP, Data and IT

Dr. Samir Padalkar  joined Omega Therapeutics as Vice President of Data and IT bringing over 30 years of distributed real-time and data science experience with an extensive background in healthcare, financial trading, process control, and IoT. He is an industry leader in Big Data/AI-ML technology application with proven success in creating digital innovations across varying industries.

Prior to joining Omega, Samir founded Numeric Trails; a company that focused on providing data, analytics and computational expertise to leading organizations such as NYC Dept. of Health, Sumitomo Mitsui, and Honeywell. Earlier in his career, he worked in several securities exchange and financial businesses such as HOLD Brothers and Tradeweb. Samir began his career at a startup, Quant Trading, which developed one of the first off-the-shelf real-time fixed income & derivatives trading system, and was eventually acquired by Thomson Financial.

Dr. Samir Padalkar received his M.S. and Ph.D. in Electrical Engineering from Vanderbilt University, working in the distributed real-time systems lab that later became the Institute for Software Integrated Systems. He received his B.Tech. in Electronics Engineering from the Indian Institute of Technology – Madras.

OMEGA THERAPEUTICS BOARD OF DIRECTORS

Noubar Afeyan, Ph.D.

Co-Founder and Chairman of the Board, Omega Therapeutics, CEO Flagship Pioneering

X

Noubar Afeyan, Ph.D. | Co-Founder and Chairman of the Board, Omega Therapeutics, CEO Flagship Pioneering

Noubar Afeyan has dedicated his career to improving the human condition by systematically creating science-based innovations that serve as the foundation for startup companies. Flagship has fostered the development of more than 100 scientific ventures resulting in $30 billion in aggregate value, thousands of patents and patent applications and more than 50 drugs in clinical development.

Prior to founding Flagship Pioneering, Dr. Afeyan was the founder and CEO of PerSeptive Biosystems, a leader in bio-instrumentation that grew to $100 million in annual revenues. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, he became senior vice president and chief business officer of Applera, where he initiated and oversaw the creation of Celera Genomics. He serves on the boards of a number of public and private Flagship companies, has written numerous scientific publications and is the inventor of more than 80 patents.

Dr. Afeyan was born in Beirut to Armenian parents in 1962, did his undergraduate work at McGill University in Montreal and completed his Ph.D. in biochemical engineering at MIT in 1987. A passionate advocate of the contributions of immigrants to economic and scientific progress, Dr. Afeyan received the Golden Door Award in 2017 from the International Institute of New England in honor of his outstanding contributions to American society as a U.S. citizen of foreign birth.

luke beshar
Luke M. Beshar, CPA

Former Executive Vice President and CFO, NPS Pharmaceuticals

X

Luke M. Beshar, CPA | Former Executive Vice President and CFO, NPS Pharmaceuticals

Luke M. Beshar is an experienced biopharmaceutical executive and financial expert. During his tenure at NPS Pharmaceuticals, Mr. Beshar oversaw financial management, investor relations, technical operations, information technology, quality assurance, project management, contracts & outsourcing, and facilities. Prior to this role, he served as Executive Vice President, Strategy and Corporate Development and Chief Financial Officer of Cambrex Corporation and as Chief Financial Officer of Dendrite International.

Earlier in his career, Mr. Beshar held various general and financial management positions of increasing responsibility. He began his career at Arthur Anderson & Co. and is a Certified Public Accountant. Currently, Mr. Beshar serves on the board of directors of Protara Therapeutics, REGENXBIO Inc. and Trillium Therapeutics.

Mr. Beshar holds a B.S. degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia and is a Certified Public Accountant.

Mahesh Karande

President & CEO, Board Director

X

Mahesh Karande | President & CEO, Board Director

Mahesh Karande is deeply experienced in running biopharma businesses across discovery, preclinical development, clinical development, commercialization and product life cycle management stages. His breadth of therapeutic experience spans cardiovascular and metabolic, oncology, neurosciences, ophthalmology, antibiotics, pain, respiratory and rare and genetic diseases as well as drug and device combinations. He has been involved with more than 10 product launches in the U.S. and across global markets.

He has strong leadership, operational and business-building experiences combined with a global work history spanning the U.S., Europe, Asia and Africa.

Prior to taking the helm at Omega, Mr. Karande was President and CEO of Macrolide Pharmaceuticals, a company he took from discovery into early development. Earlier, Mr. Karande spent several years at Novartis in senior leadership roles: VP and Head of US Oncology for solid tumors, President of Novartis Africa and President of Novartis Egypt. He worked for McKinsey & Company prior to joining the bio-pharmaceutical industry.

Mr. Karande has an M.B.A. from the Wharton School, University of Pennsylvania. He is also a graduate of the Georgia Institute of Technology where he completed his M.S. in engineering and the University of Bombay where he completed undergraduate studies in engineering.

elliott levy
Elliott Levy, M.D.

Former Vice President of Global Development, Amgen

X

Elliott Levy, M.D. | Former Vice President of Global Development, Amgen

Elliott Levy has served as Senior Vice President of Global Development of Amgen since September 2014 and Senior Vice President of R&D Strategy and Operations since June 2020. He served as Chairman of the board of TransCelerate BioPharma, Inc. from September 2017 to September 2019 and as a board member since May 2015. 

Dr. Levy received his M.D. from Yale University and his B.A from Yale College.

John Mendlein, Ph.D.

Executive Partner, Flagship Pioneering

X

John Mendlein, Ph.D. | Executive Partner, Flagship Pioneering

John Mendlein, Ph.D., is an Executive Partner at Flagship Pioneering and longtime member of Flagship’s broader ecosystem of companies. He is a highly experienced biotech leader and has served in numerous executive and board roles. John is co-author or co-inventor of over 210 publications and published patents. He has served on the boards of the Biotechnology Innovation Organization (BIO), as well as on Moderna (NASDAQ: MRNA), Axcella Health and Editas Medicine (NASDAQ: EDIT). John currently serves as the Chairman of the Board of Directors at at Senda Biosciences.

John holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami.

Mary Szela

TriSalus Life Sciences, President & CEO

X

Mary Szela | TriSalus Life Sciences, President & CEO

Mary Szela has more than 32 years of experience as an executive in the biotechnology and pharmaceutical industry, serving on the board of directors of publicly held companies Receptos Inc., Novo Nordisk and Novelion Therapeutics. Ms. Szela currently serves on the board of Coherus Biosciences, Kura Oncology, Alimera Sciences and TriSalus Life Sciences. Prior to joining TriSalus, Ms. Szela was chief executive officer of Novelion Therapeutics, where she resolved the significant legal, regulatory and compliance issues facing the company and executed a merger to recapitalize the company within the first year.

Ms. Szela earned a B.S. in nursing and an MBA from the University of Illinois at Chicago.

Rick Young, Ph.D.

MIT Professor of Biology, Member, Whitehead Institute

X

Rick Young, Ph.D. | MIT Professor of Biology, Member, Whitehead Institute

Dr. Rick Young studies gene regulatory circuitry in health and disease. His research accomplishments range from the development of genome-wide analysis technologies to the discovery of core regulatory circuitry of human embryonic stem cells. He has served as an advisor to the National Institutes of Health, the World Health Organization, the Vatican and numerous scientific societies and journals. Dr. Young has founded and advised companies in the biotechnology and pharmaceutical industry and is currently a member of the board of directors of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics and Dewpoint Therapeutics.

Dr. Young received his Ph.D. in molecular biophysics and biochemistry at Yale University, conducted postdoctoral research at Stanford University and joined Whitehead Institute and MIT in 1984.